Abstract

Cancer cells exhibit a heightened dependency on glutamine metabolism to sustain their rapid proliferation and survival. Targeting this metabolic vulnerability has emerged as a promising therapeutic strategy. This paper explores the role of glutamine metabolism in cancer, the mechanisms of therapeutic resistance, and strategies to overcome these challenges. Advances in research, including metabolomics and tumor microenvironment studies, enhance our understanding of cancer metabolism. Clinical trials are evaluating various glutamine-targeted therapies, showing promising results. Translational potential is high, with efforts focused on personalized treatment approaches. Despite challenges, the future of targeting glutamine metabolism in cancer treatment is promising, with significant opportunities for developing effective therapies.